Alkermes Plc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Alkermes Plc in the second quarter 2026?
Alkermes Plc achieved a return on average equity (ROE) of 3.72 % in its second quarter 2026, this is above ALKS's average return on equity of -2.92%.
Alkermes Plc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $1,778 million

ROE fell compared to the first quarter 2026, despite the net income growth of % from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 59 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1567 to 1591.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	11.32 %	15.87 %	24.19 %	34.16 %	-
Y / Y Net Income Change	-99.42 %	-	-66.32 %	-10.41 %	-4.66 %
Net Income (TTM) in Millions	66	153	242	339	348
Return On Equity (TTM)	3.72 %	8.82 %	14.45 %	21.4 %	23.65 %
ALKS's Total Ranking	# 1591	# 1567	# 841	# 524	# 428
Equity (TTM) in Millions	1,809	1,752	1,819	1,733	1,625
Seq. Equity Change	3.26 %	-3.72 %	4.95 %	6.7 %	7.48 %
Seq. Net Income Change	-	-	-40.38 %	-4.98 %	287.72 %

Back to ALKS Management Effectiveness >> ALKS's 5 Years Annual ROE >> Compare ALKS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 60
Sector	# 171
Overall	# 1591

Return On Equity Statistics
High	Average	Low
34.12 %	-2.92 %	-21.2 %
(Mar 31 2024)		(Jun 30 2016)

ALKS Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,819	1,465	1,203	1,044	1,113
Y / Y Equity Change	24.19 %	21.81 %	15.23 %	-6.19 %	4.27 %
Net Income in Millions	242	367	356	-158	-48
Y / Y Net Income Change	-34.16 %	3.18 %	-	-	-
Return On Equity	13.28 %	25.06 %	29.58 %	-15.16 %	-4.33 %

Back to ALKS Management Effectiveness >> ALKS's 5 Years Annual ROE >> Compare ALKS ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 13.28 %, due to deterioration of net income.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ALKS's' Return on Equity at Yahoo Finance
ALKS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ALKS's Competitors
Subscribers only: Roe for Alkermes Plc 's Suppliers
Subscribers only: Return On Equity for ALKS's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
The Pennant Group Inc	10.18 %
Amphastar Pharmaceuticals Inc	10.11 %
Align Technology inc	10.09 %
Ardent Health Inc	9.92 %
Edwards Lifesciences Corporation	9.65 %
Addus Homecare Corp	9.57 %
IMPACT BIOMEDICAL INC.	9.56 %
Teva Pharmaceutical Industries Limited	9.11 %
Merit Medical Systems Inc	9.07 %
Bio techne Corp	9.01 %
Utah Medical Products Inc	8.74 %
Vaso Corporation	8.65 %
Veracyte Inc	8.64 %
Corcept Therapeutics Inc	8.27 %
Integer Holdings Corporation	7.43 %
Pacific Health Care Organization Inc	7.42 %
Vericel Corporation	6.91 %
The Cooper Companies Inc	6.90 %
Siga Technologies Inc	6.74 %
Merck and Co Inc	6.59 %
Zimmer Biomet Holdings Inc	6.36 %
National Vision Holdings Inc	5.71 %
Conmed Corporation	5.51 %
Pfizer Inc	4.91 %
Privia Health Group Inc	4.23 %
Becton Dickinson And Company	3.79 %
Alkermes Plc	3.72 %
Lifemd Inc	3.47 %
Lifestance Health Group Inc	3.39 %
Revvity Inc	3.27 %

Date modified: 2026-09-26T06:58:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.